Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Sant P. Chawla, Lee D. Cranmer, Brian A. Van Tine, Damon R. Reed, Scott H. Okuno, James E. Butrynski, Douglas R. Adkins, Andrew E. Hendifar, Stew Kroll, Kristen N. Ganjoo

Research output: Contribution to journalArticlepeer-review

127 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma'. Together they form a unique fingerprint.

Medicine & Life Sciences